 |
|
Leukemia Trial Results
1. Rituximab Improves Outcomes for Patients With Chronic Lymphocytic Leukemia
(Posted: 01/14/2009) - Advanced chronic lymphocytic leukemia patients who received the monoclonal antibody rituximab in addition to standard chemotherapy with fludarabine and cyclophosphamide (FC) had outcomes far better than those patients who received FC alone, according to studies presented December 2008 at the American Society of Hematology meeting.
2. High Dose Chemotherapy Significantly Prolongs Survival for Patients with Acute Myeloid Leukemia
(Posted: 11/17/2008) - Preliminary results from a large, randomized clinical trial for patients ages 16 to 60 with previously untreated acute myeloid leukemia, a cancer of the blood and bone marrow, show that patients who received a high dose of a commercially available chemotherapy drug, daunorubicin, during initial therapy lived longer than patients who received a standard dose of the same drug.
3. Allogeneic (Donor) Stem-Cell Transplant Boosts Survival in Ph-Negative, Standard-Risk ALL
(Posted: 01/07/2008) - In the largest-ever clinical trial of treatment for adults with acute lymphoblastic leukemia (ALL), patients with standard-risk, Philadelphia-chromosome-negative ALL lived significantly longer after chemotherapy-induced first remission when they received allogeneic (donor) stem-cell transplantation instead of continued chemotherapy, according to a Nov. 29, 2007, report issued by Blood.
4. Dasatinib and Nilotinib Both Effective for CML When Imatinib Won't Work
(Posted: 10/31/2007) - Two new targeted drugs - dasatinib (Sprycel®) and nilotinib (Tasigna®) - are effective in most patients with chronic myelogenous leukemia who cannot take or who have become resistant to imatinib (Gleevec®), according to two 2007 reports in the journal Blood.
5. Dasatinib Effective Against Difficult-to-Treat Acute Lymphoblastic Leukemia
(Posted: 06/01/2007) - The multitargeted drug, dasatinib (Sprycel) may be extremely beneficial in adult patients with a form of acute lymphoblastic leukemia (ALL) who have developed resistance or do not respond to another targeted agent, imatinib mesylate (Gleevec), according to the May 11, 2007, issue of the journal Blood.
1 2 3 4 Next >
|
|
|
